MB Comment: Here is the latest piece of pseudo-scientific research to come down the pike pushing for male HPV vaccination (Gardasil). This 10,000 word medical journal article was obviously written by academic know-nothings who can’t even get to first base with regard to the real-life issues about vaccination. This article does not contain a SINGLE WORD about adverse events associated with this vaccine.
The latest FDA data show 115 reports of deaths after HPV vaccination (108 Gardasil, 7 Cervarix). There are currently 26,069 FDA adverse event reports for HPV vaccines, with numerous cases of neurological damage, blood clots, etc.
Here’s a quote from one FDA adverse reaction report: ‘the patient was vaccinated with a second dose of GARDASIL (lot number, injection site and route not reported). Subsequently the patient died. The cause of death was reported as allergic reaction to GARDASIL.’
This absurd medical journal article is a perfect example of why educated, informed parents should not trust the system that determines which vaccines are administered to their children. This article will undoubtedly be referenced by policy makers when they attempt to make Gardasil mandatory for boys for school attendance, etc.
Here is the key information that this article omits: From the Merck Gardasil PACKAGE INSERT (page 11)
The following adverse events have been spontaneously reported during post-approval use of GARDASIL …
General disorders and administration site conditions: Asthenia, chills, death, fatigue, malaise.
Immune system disorders: Autoimmune diseases, hypersensitivity reactions including anaphylactic/anaphylactoid reactions, bronchospasm, and urticaria.
Musculoskeletal and connective tissue disorders: Arthralgia, myalgia.
Nervous system disorders: Acute disseminated encephalomyelitis, dizziness, Guillain-Barré syndrome, headache, motor neuron disease, paralysis, seizures, syncope (including syncope associated with tonic-clonic movements and other seizure-like activity) sometimes resulting in falling with injury, transverse myelitis …
Vascular disorders: Deep venous thrombosis.
Can Male Vaccination Reduce the Burden of Human Papillomavirus-Related Disease in the United States?
Garren M.I. Low, Yasser S. Attiga, Gaurav Garg, Richard Schlegal, and G. Ian Gallicano. Viral Immunology. June 2012, 25(3): 174-186. doi:10.1089/vim.2011.0083. Published in Volume: 25 Issue 3: June 12, 2012
‘ … Marketing campaigns in the U.S. which are focused on even the most pressing HPV-related health concerns in women have failed to induce compliance with vaccination recommendations. As described above, the net result has been a low rate of vaccination, and potentially decreasing rates of screening for cervical cancer in the U.S. (75). Since vaccinating additional females seems to be increasingly difficult in the U.S. (4), vaccination of males becomes an ever-more viable option for increasing herd immunity to HPV …
Because funding for vaccination campaigns is scarce, economic analyses in conjunction with public health and social welfare considerations are necessary for determining the cost-effectiveness of including males in strategies for HPV vaccination programs …
Since the vaccines have only been available for few years, we do not yet have a full understanding of the longevity and efficacy of the vaccine in males …
While definitive literature on the economics of vaccinating men still seems to be forthcoming, it is clear that HPV vaccination in boys is highly expensive compared to girls-only programs …
we can say that girls-only vaccination programs, without a doubt, represent a more economically efficient option than extending the same preventive measures to boys. As such, if scarcity of resources requires a choice to be made, we can ensure greater health return for our investment by vaccinating girls. From an economic perspective, we should consider vaccination of boys only if the availability of additional resources permits …
Several countries are subscribing to the idea of including males in the vaccination process to help eradicate HPV more effectively. Countries such as Canada, Mexico, and Australia have already licensed the use of HPV vaccines in males (1,31), and the FDA recently approved the use of Gardasil in males to prevent genital warts in the United States. Vaccination of males could one day be the ideal solution to diminish the prevalence of HPV.
The two current vaccines on the market, Gardasil and Cervarix, have been proven to be highly effective against HPV types 16 and 18, which account for 70% of cervical cancer cases. The current marketing of the vaccine is directed towards prevention of cervical cancer specifically. In order to encourage male participation in HPV vaccination in the United States, a new marketing campaign would have to be developed that outlines the other risks of HPV infection, while describing the potential role of the vaccine in mitigating those undesirable outcomes. In conjunction with this marketing push, vaccination for HPV could be added to the normal vaccination schedules for adolescent males and females.‘